✦ LIBER ✦

ABSORB II randomized controlled trial: A clinical evaluation to compare the safety, efficacy, and performance of the Absorb everolimus-eluting bioresorbable vascular scaffold system against the XIENCE everolimus-eluting coronary stent system in the treatment of subjects with ischemic heart disease caused by de novo native coronary artery lesions: Rationale and study design

✍ Scribed by Roberto Diletti; Patrick W. Serruys; Vasim Farooq; Krishnankutty Sudhir; Cecile Dorange; Karine Miquel-Hebert; Susan Veldhof; Richard Rapoza; Yoshinobu Onuma; Hector M. Garcia-Garcia; Bernard Chevalier

Book ID: 119183568
Publisher: Elsevier Science
Year: 2012
Tongue: English
Weight: 419 KB
Volume: 164
Category: Article
ISSN: 1097-6744
DOI: 10.1016/j.ahj.2012.08.010

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Comparison of Everolimus-Eluting and Pac

Comparison of Everolimus-Eluting and Paclitaxel-Eluting Coronary Stents in Patients Undergoing Multilesion and Multivessel Intervention: The SPIRIT III (A Clinical Evaluation of the Investigational Device XIENCE V Everolimus Eluting Coronary Stent System [EECSS] in the Treatment of Subjects With De Novo Native Coronary Artery Lesions) and SPIRIT IV (Clinical Evaluation of the XIENCE V Everolimus Eluting Coronary Stent System in the Treatment of Subjects With De Novo Native Coronary Artery Lesions) Randomized Trials

✍ Dean J. Kereiakes; Krishnankutty Sudhir; James B. Hermiller; Paul C. Gordon; Joa 📂 Article 📅 2010 🏛 American College of Cardiology 🌐 English ⚖ 939 KB